No Data
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
J.P. Morgan Maintains Pacira BioSciences(PCRX.US) With Buy Rating
J.P. Morgan analyst Hardik Parikh maintains $Pacira BioSciences(PCRX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 50.0% and a total average return of -3.2%
Pacira BioSciences: Medicare and Medicaid Propose New Reimbursement for Exparel
By Stephen Nakrosis Pacira BioSciences said the U.S. Centers for Medicare and Medicaid Services have proposed new reimbursement for its Exparel non-opiod pain relief medicine in all outpatient
Express News | Pacira BioSciences Announces Centers For Medicare And Medicaid Services Issued Proposed Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Rule For 2025; Proposes New Reimbursement For EXPAREL
Express News | Centers for Medicare and Medicaid Propose New Reimbursement for Exparel in All Outpatient Surgical Environments Beginning January 1, 2025
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
PDF Version-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital